GIP-agonisten kunnen deze werking volgens de onderzoekers mogelijk versterken
A patient may tolerate treatment for several weeks and then experience nausea, diarrhea, fullness, or reflux again after a clinician-directed dose increase
Anemia from another cause, thyroid disease, iron deficiency, folate deficiency, inflammatory disease, and metabolic contributors can all produce overlapping complaints, as can medication effects, sleep disorders, and neurologic conditions
Research-grade peptides should have batch-specific Certificates of Analysis showing third-party HPLC purity testing and mass spectrometry molecular identity confirmation, plus peptide content verification confirming the actual peptide mass per vial
Taken together, GCGR agonism offers a promising yet complex strategy in cardiometabolic disease, as it promotes weight loss and energy expenditure while also increasing blood glucose, underscoring the need for dual- and triple-agonist approaches (GLP1R/GIPR/GCGR) that balance metabolic and CV effects
CCH: collagenase clostridium histolyticum
